Jakafi PV launch pushes up Incyte's 1Q sales
This article was originally published in Scrip
Executive Summary
Incyte's AK 1 and 2 tyrosine kinase inhibitor, Jakafi (ruxolitinib), has beaten expectations in the first quarter of 2015 following the launch of the product in new indication polycythemia vera.